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1. Introduction  
Gene delivery involves the introduction of exogenous genetic mate-
rial to somatic cells of patients with the subsequent expression of a 
therapeutic molecule. Because all basic physiological processes are 
regulated by gene expression, gene delivery strategies represent 
an enormous potential for therapeutic treatment of numerous dis-
eases as well as an alternative method for vaccination [1]. Currently, 
gene delivery is accomplished by means of two main delivery sys-
tems: viral and non-viral systems. While viral delivery vectors are ex-
tremely efficient in delivering DNA in vitro and in vivo, there remains 
concerns with their toxicity, the potential of generating unwanted 
immune responses, and their limited DNA cargo capacity. Non-vi-
ral delivery systems, which typically make use of cationic polymers 
or lipids to electrostatically combine with, or physically encapsulate 
DNA, can overcome many of the toxicity and immune concerns of 
viral vectors. However, they suffer from low delivery efficiency, high-
lighting the need for non-viral vectors that improve transgene de-
livery while remaining non-toxic.  
Of the many routes of administration for non-viral gene deliv-
ery systems, the oral route is preferable due to high patient compli-
ance and the ease of administration and dosing [2,3]. The oral route 
is of particular interest for the applications of gene therapy and DNA 
vaccination due to continuously cycling cells of the intestinal epi-
thelium, which present a large cellular surface area for transfection 
with a therapeutic gene [4]. Additionally, the highly vascularized na-
ture of the intestinal epithelium [5] facilitates both local (e.g. Crohn’s 
disease [6] and ulcerative colitis [7]) and systemic therapies (e.g. di-
abetes [8], hemophilia A [9,10] and B [11], and hypoparathyroidism 
[12]). Because of the potential for treating both local and systemic 
diseases, gene therapy via oral delivery has been an area of intense 
focus in recent years [6,11,13,14].  
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Abstract
The oral route is an attractive delivery route for the administration of DNA-based therapeutics, specifically for applications in 
gene therapy and DNA vaccination. However, oral DNA delivery is complicated by the harsh and variable conditions encountered 
throughout gastrointestinal (GI) transit, leading to degradation of the delivery vector and DNA cargo, and subsequent inefficient 
delivery to target cells. In this work, we demonstrate the development and optimization of a hybrid-dual particulate delivery sys-
tem consisting of two natural biomaterials, zein (ZN) and chitosan (CS), to mediate oral DNA delivery. Chitosan-Zein Nano-in-Mi-
croparticles (CS-ZN-NIMs), consisting of core Chitosan/DNA nanoparticles (CS/DNA NPs) prepared by ionic gelation with sodium 
tripolyphosphate (TPP), further encapsulated in ZN microparticles, were formulated using a water-in-oil emulsion (W/O). The re-
sulting particles exhibited high CS/DNA NP loading and encapsulation within ZN microparticles. DNA release profiles in simulated 
gastric fluid (SGF) were improved compared to un-encapsulated CS/ DNA NPs. Further, site-specific degradation of the outer ZN 
matrix and release of transfection competent CS/ DNA NPs occurred in simulated intestinal conditions with CS/DNA NP cores suc-
cessfully mediating transfection in vitro. Finally, CS-ZN-NIMs encoding GFP delivered by oral gavage in vivo induced the produc-
tion of anti-GFP IgA antibodies, demonstrating in vivo transfection and expression. Together, these results demonstrate the suc-
cessful formulation of CS-ZN-NIMs and their potential to improve oral gene delivery through improved protection and controlled 
release of DNA cargo.  
Keywords: Oral delivery, DNA delivery, Zein, Chitosan, Gene therapy, DNA vaccination  
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In addition to gene therapy, the oral route of delivery is also con-
sidered to be highly promising as an administration route for DNA 
vaccines. DNA vaccination involves the delivery of plasmid DNA con-
taining a transgene encoding a disease-specific target antigen driven 
by a eukaryotic promoter, resulting in the intracellular production 
and subsequent sampling of the target antigen by professional an-
tigen presenting cells (APCs) [15,16]. DNA vaccines are an attractive 
alternative to traditional vaccine strategies, most of which are largely 
protein based and often fail to generate complete cell and antibody-
mediated immune responses [17]. Orally delivered DNA vaccines 
have the additional advantage of being able to target mucosal mem-
branes (i.e. intestinal mucosa) to generate mucosal immunity [18] 
while also meeting the requirements for effective global mobiliza-
tion (i.e. no dependence on “cold chain” storage and transportation). 
Despite the enormous potential of oral gene therapy and DNA 
vaccination strategies, the efficient delivery of DNA-based therapeu-
tics via the oral route is complicated by the harsh environment of the 
gastrointestinal (GI) tract (i.e., low pH, gastric enzymes and endog-
enous nucleases) and the low permeability of the intestinal epithe-
lium. Numerous efforts at achieving oral delivery have been made 
employing several synthetic [12,19,20] and natural polymers [11,21] 
as well as lipid based formulations [22]. However, those systems of-
ten yield only modest transgene expression due to the instability of 
the delivery systems. In order to overcome stability issues, recent 
attempts at oral DNA delivery have focused on the use of dual ma-
terial systems, taking advantage of differing material properties to 
protect the encapsulated payload through gastric transit and al-
low for efficient delivery at the site of interest [1,6,23,24]. However, 
these systems make use of synthetic materials with very slow deg-
radation rates that limit the release and subsequent delivery of the 
DNA cargo and require harsh solvents and fabrication techniques 
that may compromise DNA integrity.  
Zein (ZN), the major prolamine from corn, is a natural biomate-
rial that has received recent attention for gene delivery and tissue 
engineering applications due to its inherent biocompatibility and 
degradability [25,26]. Being amphiphilic in nature, ZN has the abil-
ity to self-assemble into a variety of micro and nanostructures in-
cluding nanoparticles [27, 28], microparticles [29,30], fibers [31,32], 
and films [33,34]. Moreover, ZN can be processed using simple tech-
niques including coacervation [35], phase separation [36], emulsion 
with solvent evaporation [37], anti-solvent precipitation [38], and 
liquid-liquid dispersion [39], and can successfully encapsulate a va-
riety of hydrophobic and hydrophilic compounds, including vita-
mins [40], antibiotics [41], essential oils [42], and, in our previous 
study, DNA [26].  
ZN’s insolubility in aqueous conditions, resistance to gastric en-
zymes and acidic pH, and rapid degradation in the presence of in-
testinal enzymes, make it an ideal candidate for an oral delivery vehi-
cle. To date, ZNhas been investigated as an oral drug delivery system 
for reactive oxygen species scavengers [43], insulin [44], protein an-
tigens [35], steroid drugs for inflammatory bowel disease [45], and 
antioxidants [46]. However, ZN is not suitable for gene delivery ap-
plications by itself due to its high stability in physiological condi-
tions and subsequent slow release of encapsulated DNA leading 
to inadequate transfection levels [26]. The inability of ZN to medi-
ate efficient transfection highlights the need for a secondary ma-
terial to fully realize the potential of ZNas an oral gene delivery ve-
hicle. Chitosan (CS), another natural polymer, has been widely used 
in oral non-viral gene delivery applications including gene therapy 
and DNA vaccination, and is uniquely suited for intestinal delivery 
due to its mucoadhesive nature and stability in intestinal condi-
tions. However, CS is unstable in gastric conditions due to its sol-
ubility in acidic aqueous conditions [47], highlighting the need for 
a second, gastric-protective outer material. In this study, we report 
the development of a CS/ DNA-ZN nano-in-microparticle (CS-ZN-
NIM) dual-particulate oral DNA delivery system, consisting of inner 
CS/DNA NP cores further encapsulated in ZN microparticles, using 
a single water-in-oil (W/O) emulsion. We hypothesize that the outer 
ZN microparticle protects the DNA cargo though gastric transit, and 
upon reaching the small intestine, rapidly and completely degrades 
via enzymatic action to release chitosan/ DNA nanoparticles (CS/
DNA NPs) capable of being internalized by and transfecting cellu-
lar targets in the small intestine. We provide evidence of ZN-medi-
ated protection of CS/DNA NPs from-simulated gastric fluid (SGF), 
their release from ZN microparticles following simulated in vitro GI 
transit, and transgene expression mediated from CS-ZN-NIMs sub-
jected to simulated GI fluid treatment. Furthermore, we provide ev-
idence of in vivo transgene expression following oral delivery of CS-
ZNNIMs to mice, and subsequent activation of a mucosal immune 
response, highlighting the potential of this oral delivery system for 
use in DNA vaccination and gene therapy applications.  
 
2. Materials and methods
  
2.1. Materials, cell lines, and cell culture  
Chitosan oligosaccharide lactate (Avg MW 5000), pepsin from por-
cine gastric mucosa, chitosanase from Streptomyces sp., sodium tri-
polyphosphate (TPP), petroleum ether, lysozyme from chicken egg 
white and Whatman No. 5 qualitative filter papers were purchased 
from Sigma-Aldrich (St. Louis, MO). Pancreatin, USP grade from por-
cine pancreas was purchased from MP Biomedicals (Santa Ana, CA). 
F4400 ZN was purchased from Freeman Industries LLC (Tuckahoe, 
NY). Hoechst 33258 nuclei stain was purchased from Life Technolo-
gies (Eugene, OR). 32P radio-labeled deoxyadenosine triphosphate 
and Ultima Gold liquid scintillation cocktail was purchased from Per-
kin Elmer (California, USA). The DNA Nick Translation System for ra-
diolabeling plasmid DNA was purchased from Invitrogen Life Tech-
nologies (Carlsbad, CA). Water-soluble tetrazolium salt (WST-1) cell 
proliferation reagent was purchased from Roche Life Sciences (In-
dianapolis, IN). Human embryonic epithelial kidney cells, HEK 293T 
(ATCC, Manassas, VA), were cultured in T-75 flasks in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco/Invitrogen, Carlsbad, CA) 
containing 4.5 g/L glucose and 2 mM L-glutamine (Gibco), and sup-
plemented with 10% fetal bovine serum (FBS, Gibco), and 1% pen-
icillin/streptomycin (Gibco) and 100mM sodium pyruvate at a final 
concentration of 1%. Human colon carcinoma cells, Caco-2 (ATCC) 
were cultured in T-75 flasks in Eagle’s minimum essential medium 
(EMEM, ATCC) supplemented with 20% FBS (Gibco) and 1% penicil-
lin/streptomycin (Gibco). Mouse macrophages, RAW 264.7, (ATCC) 
were cultured in T-25 flasks in DMEM (Gibco) supplemented with 
10% FBS and 1% penicillin/streptomycin. ELISA flat-bottom immu-
noMaxiSorp 96 well plates were purchased from Fisher Scientific 
(Pittsburgh, PA). Recombinant green fluorescent protein (GFP) from 
A. Victoria was purchased from Abcam (Cambridge, MA). Alkaline 
phosphatase conjugated goat anti-mouse IgA antibody and p-ni-
trophenol phosphate one component microwell substrate were pur-
chased from SouthernBiotech (Birmingham, AL).  
 
2.2. Mice  
Male BALB/cByJ mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). Mice 6–8 weeks old were used in all experiments. 
Experimental animal procedures using mice were approved by and 
conducted in accordance with the Institutional Animal Care and Use 
Committee (IACUC) at the University of Nebraska-Lincoln.  
 
2.3. Plasmid preparation and 32P radiolabeling of plasmid  
All transfection experiments were performed using the pEGFP-LUC 
(Clontech, Mountain View, CA) plasmid encoding for both firefly lu-
ciferase protein and green fluorescent protein under the direction 
of the CMV promoter. The plasmid was purified from E. coli using 
a Qiagen Giga kit (Valencia, CA) and stored in Tris-EDTA (TE) buffer 
solution (10 mM Tris, 1 mM EDTA, pH 7.4) at −20° until use. Plasmid 
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DNA (pEGFP-LUC) was radiolabeled with 32P α-dATP (3000 Ci/mmol, 
250 μCi) using the Invitrogen Nick Translation System according to 
the manufacturer’s protocol with minor modifications. Briefly, a total 
of 6 μg of pEGFP-LUC plasmid (1 μg/μL)was diluted to 100 ng/μL in 
TE buffer, to which 6nmol of dNTPmixminus dATP, 250 μCi of 32Pα-
dATP, ultrapure H2O, and DNA Polymerase I/DNase I mix were added. 
The reaction was allowed to run for 60 min at 15 °C, at which point 
10 μL stop buffer was added. The resulting labeled DNA was puri-
fied using a QiagenMiniPrep kit and diluted with unlabeled pEGFP-
LUC plasmid to a final concentration of 0.801 μg/μL  
 
2.4. Formation of CS/DNA NPs  
CS/DNA NPs encapsulating pEGFP-LUC were prepared using a mod-
ified version of the methods described by Calvo et al. [48] based on 
the ionic gelation of CS with TPP. A 5 mg/mL solution of CS oligo-
saccharide lactate was made by dissolving the CS in ultrapure wa-
ter. The resulting solution was filtered with a 0.22 μm syringe filter 
(EMDMillipore, Billerica, MA) to remove any impurities. Similarly, a 
0.5 mg/mL TPP solution was prepared in ultrapure water. To prepare 
the nanoparticles, the stock 5.0 mg/mL CS solution was diluted in 
ultrapure water to achieve various chitosan concentrations (0.5–2.0 
mg/mL). Plasmid DNA in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4) 
was added to the TPP solutions, mixed thoroughly and then the TPP/
DNA solution was added dropwise to the CS solution. The result-
ing NP suspension was immediately vortexed for 15 s and then al-
lowed to incubate at room temperature for 20 min. The amount of 
TPP solution used in the particle formulation was varied to achieve 
various CS:TPP ratios (w/w). For all characterization and transfection 
studies, the amount of DNA used in particle formation was held con-
stant at 10% (w/w) of the amount of CS used in the formulation, un-
less otherwise noted.  
 
2.5. Characterization of CS/DNA NPs and determination of DNA 
encapsulation efficiency  
The size and zeta potential of the CS/DNA NPs was determined by 
dynamic light scattering and Laser Doppler micro-electrophoresis, 
respectively, using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., 
UK). Size measurements were taken at 25 °C at a scattering angle of 
90° and size was reported as the Z-average diameter. Zeta potential 
measurements were also taken at 25 °C using folded capillary cells 
with the measurement mode set to automatic. DNA encapsulation 
efficiency of the CS NPs was determined by measuring the amount 
of free DNA in the aqueous particle suspension after particle for-
mation. Freshly prepared NPs were centrifuged at 10,000 × g for 20 
min and the amount of DNA in the supernatant was measured using 
the Hoechst assay. Briefly, supernatant samples were diluted in 1× 
TNE buffer (10 mM Tris; 0.2 M NaCl; 1 mM EDTA; pH 7.4) to a final 
volume of 1 mL and mixed with 1 volume of a 200 ng/mL solution 
of Hoechst 33258 dye. After a 5-min incubation at room tempera-
ture, fluorescence was measured using a modulus luminometer/flu-
orometer (Turner Biosystems, Sunnyvale, CA). The encapsulation ef-
ficiency of the CS NPs was determined by calculating the difference 
between the amount of measured free DNA and the initial amount 
of DNA used in the particle preparation according to Eq. (1): 
   
EE% =
 Initial amount of DNA used in particle preparation − DNA in supernatant 
                          Initial amount of DNA used in particle preparation 
(1)
 
2.6. Transfection efficiency of CS/DNA NPs  
Transfection studies with CS/DNA NPs encapsulating pEGFP-
LUC were performed using the human embryonic kidney cell line 
(HEK293T). Cells were seeded in 48 well plates at a seeding den-
sity of 33,000 cells/well in a total of volume of 300 μL of complete 
Dulbecco’s Modified Eagle’s Medium (DMEM) 18 h prior to delivery 
of the CS/ DNA NPs. The day of transfection, CS/DNA NPs were pre-
pared as described above. CS/DNA NPs encapsulating 1 μg of DNA 
were diluted in an appropriate volume of serum free Opti-MEM to 
deliver a total volume of 75 μL/well and then added to each well. 
The NPs were allowed to incubate with the cells for 24 h at which 
point transfection was assessed qualitatively using fluorescent mi-
croscopy. Transfection levels were quantified using the luciferase as-
say system (Promega, Madison, WI) to measure luciferase activity. 
Briefly, cells were lysed by adding 200 μL of 1 × reporter lysis buffer 
(Promega) and the cell lysates were measured for luciferase activ-
ity using a luminometer with an integration time of 10 s. Measured 
relative light units (RLU) were normalized to total protein content 
measured by the BCA protein assay (Pierce).  
 
2.7. Formation of CS-ZN NIMs  
CS/DNA NPs were encapsulated in ZN microparticles using a W/O 
emulsion with solvent evaporation technique as described in [37] 
with some modifications. Briefly, CS/DNANPs were formed as de-
scribed above and collected by centrifugation at 10,000 × g for 20 
min to remove the particles from any unbound DNA and any free 
CS. The collected NPs were then completely re-suspended in 50 μL 
of ultrapure water and subsequently added to 1.5 mL of ZN solu-
tion (5–25% w/v) previously dissolved in 90% (v/v) ethanol and pH 
adjusted to 8–9. The CS/DNA NP-ZN suspension was immediately 
added to 150 mL of cold corn oil containing 0.75% span 80 (v/v) 
stirred at a constant rate of 800 rpm on a magnetic stirrer. After the 
microparticles had completely hardened, the particles were collected 
by vacuum filtration, washed repeatedly with petroleum ether to re-
move excess oil, and oven dried at 50 °C overnight. Particles were 
stored at 4° until use.  
 
2.8. Scanning electron microscopy of CS-ZN NIMs and particle size 
determination  
CS-ZN NIMs formed as described above were oven dried for 24 h 
and then stored under vacuum prior to scanning electron micros-
copy (SEM) imaging. The microparticles were mounted to double-
sided carbon tape on brass stubs, and sputter coated with gold un-
der argon atmosphere before SEM imaging (Nova NanoSEM 450) 
Micrographs were taken at a beam voltage of 5 kV and spot size of 
3. Due to both the large size of the CS-ZN-NIMs and the interfer-
ence with DLS measurements from ZN autofluorescence, the num-
ber-average diameter of the CSZN NIMs was determined from SEM 
image analysis. Briefly, particle formulations were prepared in tripli-
cate and representative images of particles from each sample were 
analyzed using the ImageJ particle analysis tool. A minimum of 150 
particles was analyzed for sizing purposes.  
 
2.9. Determination of DNA loading and encapsulation in CS-ZN 
NIMs  
Loading and encapsulation of CS/DNA NPs into ZN microparticles 
was determined using radiolabeled DNA due to the autofluores-
cence of ZN [26], which makes the use of DNA binding dyes (e.g. 
Hoechst, PicoGreen) for measuring DNA inaccurate. Briefly, CS/DNA 
NPs were formed as previously described at varying CS:DNA ratios 
(5, 10, and 25) with 32P α-dATP labeled pEGFP-LUC. The resulting 
CS/DNA NPs were encapsulated in ZN microparticles formed from 
varying ZN solutions (12, 15, and 25% w/v) as described above. The 
particles were filtered from the oil and added to 15 mL of Ultima 
Gold liquid scintillation cocktail and counts per minute were read 
using a Packard 1900 TR Liquid Scintillation Counter. The amount 
of DNA in the particles was determined using a standard curve with 
known amounts of DNA. Loading was calculated as μg of DNA/g of 
ZN particles. DNA encapsulation was calculated as the amount of 
DNA measured in the ZN particles divided by the initial amount of 
DNA used in particle preparation (Eq. (2)): 
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EE% =
     Amount of DNA measured in the ZN particles 
     Initial amount of DNA used in particle preparation 
× 100%   (2)
2.10. Cell viability assay and CS-ZN-NIMs biocompatibility  
The biocompatibility of the CS-ZN-NIMs was assessed using the 
WST-1 cell proliferation assay. Briefly, HEK293T, Caco-2, or RAW264.7 
cells were seeded at a density of 36,000, 25,000, and 280,000 cells 
per well, respectively, in 48 well plates. Eighteen hours after plating, 
0.15 mg of CS-ZN-NIMs (formed using 12, 15, or 25% ZN) in serum 
free Optimem were added to each well. Cells and particles were 
cocultured for 24 h. Media and particles were then discarded and 
cells were washed with 200 μL of PBS. Each well received 336 μL of 
WST-1 reagent diluted at a 1:10 ratio in serum free DMEM (Gibco); 
cells and reagent were incubated for 3 h at 37 °C. After incubation, 
150 μL of the WST-1 reagent from each well was transferred to a 
96-well plate and absorbance at 430 and 690 nm was read using an 
Epoch Microplate spectrophotometer (BioTek, Winooski, VT). Empty 
wells containing only WST-1 reagent were used as a blank and ab-
sorbance values were normalized to cells that received no particles. 
2.11. Gastric release of DNA from CS-ZN-NIMs and uncoated  
CS/DNA NPs  
The release profile of DNA from CS-ZN-NIMs was determined us-
ing 32P α-dATP labeled pEGFP-LUC due to the autofluorescence of 
ZN [26]. Briefly, CS-ZN-NIMs, prepared as described above, were in-
cubated in 4 mL of SGF (0.034M NaCl, 0.085 M HCl, 3.2 g/L pepsin, 
pH ~1.2) (Gastric Fluid, USP) for varying times (0–240 min) at 37°C 
with agitation. At various time points, particles were centrifuged at 
500 g for 5 min; 2 mL of the supernatant were removed and col-
lected into 20 mL scintillation vials containing 10mL of Ultima Gold 
scintillation cocktail. The particles were then resuspended in 2 mL of 
fresh release media and the incubation continued. Upon completion 
of the release study, the particles were collected, and the DNA re-
leased at each time point, as well as the DNA remaining in the par-
ticles, were measured with a Packard 1900 TR Liquid Scintillation 
Counter. The amount of DNA in the samples was determined using 
a standard curve with known amounts of DNA and release was cal-
culated using Eq. (3):
%Release =
 Cumulative DNA collected through timepoint X 
                   [Total DNA collected throughout release study] + DNA remaining in CS−ZN−NIMs            
×100% (3)
Due to issues with resuspension of CS/DNA NPs following SGF 
incubation, measuring release from the same sample over multi-
ple time points was technically challenging. Therefore, release from 
CS/DNA NPs (without ZN) was determined by centrifuging and col-
lecting entire samples at various time points. Particles were centri-
fuged at 10,000 × g for 20 min at 4°C and the supernatant discarded. 
The remaining CS/DNA NPs were subjected to a chitosanase/lyso-
zyme digestion to release encapsulated DNA. 0.5 μL of chitosanase 
and 0.5 μL lysozyme (equivalent to 0.06 and 214 Units, respectively) 
in 400 μL of a 50 mM sodium acetate- acetic acid buffer at pH 5.5 
were added to CS/DNANPs and incubated at 37 °C for 4 h. Follow-
ing the chitosanase/lysozyme digestion, the DNA in both the di-
gested sample and supernatant was measured using the Hoechst 
assay as described above. Release from CS/DNA NPs was calcu-
lated using Eq. (4): 
%Release =
 [  Initial amount of DNA encapsulated –           ]                      DNA extracted from NPs at each time point 
Initial amount of DNA encapsulated          
× 100  (4) 
2.12. Intestinal enzyme mediated release of CS/DNA NPs from  
CS-ZN NIM and transfection profiles  
To determine the mechanism of ZN degradation and release of CS/ 
DNA NPs from CS-ZN-NIMs, a series of simulated intestinal fluid 
(SIF) incubations were performed with the particles prior to deliv-
ery to cells. Briefly, HEK293T cells were seeded at a density of 36,000 
cells per well in a 48 well plate 18 h prior to the addition of treated 
particles. The day of transfection, CS-ZN-NIMs encapsulating pEGFP-
LUC, and formed using various ZN solutions (5, 7, 10, 12, 15 and 25% 
w/v), were incubated in either 10 mL of SIF pH 6.8 containing pan-
creatin (Intestinal Fluid, USP) at 37° or 10 mL of PBS at 37 °C for 60 
min with continuous agitation. After 60 min, or varying times (0, 15, 
30, 60 min) in SIF or PBS, the CS-ZN-NIMs were filtered through a 
2.5 μmcellulose filter to remove residual ZN and residual pancreatin. 
The filtrate was collected and centrifuged at 5200 rpm for 20 min 
to collect CS/DNA NP cores. These NPs were resuspended in Opti-
MEM and 75 μL of NP suspension was added to each well of cells. 
Twenty-four hours after delivery of these “conditioned” NPs to cells, 
luciferase expression was quantified as described above.  
 
2.13. In vitro simulation of oral delivery of CS-ZN-NIMs particles 
and transfection studies  
To determine the ability of the ZN-CS-NIMs to protect the CS/DNA 
NPs through the gastric environment and subsequently release in-
tact particles for delivery in the intestinal compartment, a series of 
in vitro simulations of oral delivery were performed in simulated 
gastric and intestinal fluids. For transfection studies, HEK293T cells 
were seeded in 48 well plates at a density of 36,000 cells/well 18 h 
prior to oral delivery simulation. The day of transfection, dried CS-
ZN-NIMs encapsulating pEGFP-LUC were first incubated in 10 mL 
of SGF at pH ~1.2 containing pepsin (Gastric Fluid, USP) for 15 min 
at 37 °C. Particles were then collected by centrifugation at 5200 rpm 
for 10 min, the gastric fluid completely removed and the particles 
resuspended in 10 mL of SIF at pH 6.8 containing pancreatin (Intes-
tinal Fluid, USP) and incubated for an additional 60 min at 37°C. SIF 
containing the CS-ZN-NIMs was then filtered as described above. 
The filtrate was collected and centrifuged at 5200 rpm for 20 min to 
collect the CS/DNA NPs. After centrifugation, particles were washed 
twice with PBS and then resuspended in 240 μL of serum-free Opti-
MEM media. For delivery to cells, 75 μL of the CS/DNA NPs sus-
pended in Opti-MEM were added directly to each well. Transfection 
was qualitatively assed 24 h after transfection with fluorescent mi-
croscopy. Transfection levels were quantified using the luciferase as-
say system as described above.  
 
2.14. Oral delivery of CS-ZN-NIMs  
The ability of the CS-ZN-NIMs to mediate transgene expression 
following oral delivery was evaluated in mice. For oral delivery, 
CS-ZNNIMs (prepared using 12% ZN solution, CS:DNA ratio = 
10, CS:TPP ratio = 8) encapsulating the pEGFP-LUC plasmid were 
formed as described above. Prior to CS-ZN-NIM oral delivery, 6–8 
week old male BALB/c mice (Jackson Laboratories) were fasted 
overnight. The following day, CS-ZN-NIMs encapsulating either 
35 or 100 μg of pEGFP-LUC plasmid DNA were suspended in sa-
line and administered to mice (4 mice/treatment group) via oral 
gavage. Two mice received 20 μg of recombinant GFP adjuvanted 
with Addavax (Invivogen, San Diego, CA) via intraperitoneal injec-
tion (GFP:Addavax 1:1 (v/v) in a total volume of 500 μL) as a posi-
tive control for generating anti-GFP antibodies. A separate cohort 
of mice (3 mice/group) received either 35 or 100 μg of pEGFP-
LUC plasmid DNA encapsulated in uncoated CS/DNA NPs formu-
lated using the same conditions as those loaded into CS-ZN-NIMs 
(CS:DNA ratio = 10, CS:TPP ratio = 8). For this, CS/DNA NPs were 
formed as described above, centrifuged to remove any un-encap-
sulated DNA, resuspended in 200 μL saline, and delivered to mice 
via oral gavage.  
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2.15. Evaluation of antibody response to orally administered  
CS-ZN-NIMs: ELISA assay  
To analyze antibody production in mice treated with either CS-ZN-
NIMs, CS/DNA NPs, or recombinant GFP protein and adjuvant, fe-
cal samples were collected three weeks after the initial oral admin-
istration of CS-ZN-NIMs. Fecal samples were weighed and diluted 
at 1:20 (w/v) in PBS. An ELISA assay was performed to quantify 
anti-GFP IgA titers. For the ELISA, 96 well plates (MaxiSorp, Nunc 
USA) were coated with 50 μL of recombinant GFP protein (10 μg/
mL in 1 × PBS) and allowed to adsorb overnight before the assay 
was performed. The following day, plates were blocked for 1 h with 
blocking buffer (1× PBS, 2% FBS, 10 mM HEPES, pH 7.4). Fecal slur-
ries were added at a starting dilution of 1:20 and subsequently di-
luted 1:2 to obtain a dilution curve. Samples were incubated for 
2.5 h, extensively washed, and incubated with alkaline phospha-
tase (AP)-conjugated goat anti-mouse IgA antibody (1:1000 dilu-
tion in blocking buffer) for an additional hour. After 1 h, 50 μL of 
pNPP AP substrate reagent was added to each well and the reac-
tion was allowed to develop for 30 minutes, at which point opti-
cal densities were measured at 405 nm using an EpochMicroplate 
spectrophotometer. Endpoint titers were obtained by calculating 
the reciprocal of the fecal sample dilution at the background op-
tical density set using fecal slurries from a mouse immunized with 
irrelevant antigen.  
 
2.16. Statistical analyses  
All experiments were performed between three and six times (noted 
in figure legends). Comparative analyses were completed using ei-
ther a student’s t-test or one-way ANOVA followed by Tukey’s post-
test for comparing multiple treatment conditions, both at a 95% 
confidence level using Prism software (GraphPad Prism 5, LaJolla, 
CA). All values are reported as mean ± standard error of the mean. 
 
3. Results  
 
3.1. Characterization of CS oligosaccharide/DNA NPs: size, charge, 
DNA encapsulation and transfection efficiency  
The objective of this work was to develop CS-ZN-NIMs, which con-
sist of inner CS/DNA NP cores designed for optimal transfection that 
are further encapsulated in a ZN microparticle to improve particle 
stability and DNA protection through the GI tract for oral gene deliv-
ery applications. Because the characteristics of the CS/DNA NP inner 
cores (e.g. size, charge, DNA encapsulation)will ultimately determine 
the transfection efficiency of the system, their complete character-
ization was essential. CS/DNA NPs formed with varying weight ra-
tios of CS to TPP (from 4 to 14), and at initial CS solution concentra-
tions of 0.5 mg/mL, 1.0 mg/mL, and 2.0 mg/mL were characterized 
for size and zeta potential (Fig. 1 A-C) and DNA encapsulation (Fig. 
1 D–F). As the CS:TPP weight ratio increased, the overall diameter 
of the CS/DNA NPs increased from 197.56 to 307.47 nm for 0.5 mg/
mL CS concentrations, from 233.6 to 378.6 nm for 1.0 mg/mL CS 
concentrations, and from 299 to 421 nm for 2.0 mg/mL CS concen-
trations (Fig. 1 A–C, respectively). Similar trends were observed for 
the zeta potential measurements, with values increasing from 14.5 
to 48.1 mV, 28.9 to 44.7 mV, and 16.3 to 40.2 mV for 0.5 mg/mL CS, 
1.0 mg/mL CS and 2.0 mg/mL CS, respectively (Fig. 1 A–C). The DNA 
encapsulation efficiency of CS/DNANPs formed with varying CS:TPP 
weight ratios and CS concentrations of 0.5, 1.0, and 2.0mg/mL was 
also investigated (Fig. 1 D–F). As CS:TPP ratio increased encapsula-
tion efficiencies decreased from 91.34 to 61.74% for 0.5 mg/mL CS, 
90.75 to 62.26% for 1.0 mg/mL CS, and 99% to 45.4% for 2.0 mg/
mL CS as CS:TPP ratios increased (Fig. 1 D–F). CS/DNA NPs were also 
evaluated for their ability to mediate transgene expression in vitro. 
Transgene expression levels 24 h after transfection of HEK293T cells 
with varying CS/DNA NP formulations showed similar trends for par-
ticles formed with 0.5, 1.0 and 2.0 mg/mL initial CS concentrations 
(Fig. 1 G–I). Overall, a trend of decreasing transgene expression was 
observed as the CS:TPP weight ratios increased from 4 to 14, with 
particles formed from 2.0 mg/mL CS concentration inducing a sig-
nificantly higher transgene expression than particles formed from 
0.5 and 1.0 mg/mL CS concentrations.  
 
3.2. Formation and size characterization of CS-ZN-NIMs  
CS/DNA NPs were encapsulated in ZN microparticles using a sin-
gle W/O emulsion technique to form CS-ZN-NIMs (Fig. 2). The re-
sulting CS-ZN-NIMs were characterized for size using SEM micros-
copy and image processing techniques. The single W/O emulsion 
resulted in solid, spherical particles ranging in size from 2 μm to 30 
μm (Table 1, Fig. 3). Increasing the initial ZN solution concentration 
from 12 to 25% led to a slight increase in average particle diameter 
from 8.76 μm to 10.63 μm (Table 1, Fig. 3).  
 
3.3. CS/DNA loading and encapsulation into ZN microparticles  
Loading of CS/DNA NPs into ZN microparticles using the single W/O 
emulsion was found to be dependent upon both the initial ZN con-
centration used in the emulsion as well as the properties of the CS/
DNA NPs being loaded, specifically the weight ratio of CS to DNA 
(Table 1). Loading generally decreased as the initial ZN concentra-
tion increased, and the highest overall loadings of 185.63 and 174.46 
μg DNA/g ZN were observed at a ZN concentration of 12% with CS/
DNA NPs formed at CS:DNA ratios of 5 and 10, respectively (Table 
1). CS/DNA NPs formed at a CS:DNA ratio of 25 resulted in the low-
est loading for all ZN concentrations used. Encapsulation efficiency 
was found to be dependent on the CS:DNA ratio of the CS:DNA 
NPs loaded into the ZN microparticles (Table 1). Particles formed 
with CS/DNA NPs at a CS:DNA ratio of 10 exhibited the highest en-
capsulation efficiencies of 74, 79 and 81% for CSZN- NIMs formed 
with 12, 15 and 25% ZN solutions, respectively. CSZN- NIMs formed 
with 15 and 25% ZN and loaded with CS/DNA NPs at a CS:DNA ra-
tio of 5 and 25 showed a decrease in encapsulation efficiency to be-
low 60% (Table 1).  
 
3.4. Biocompatibility of CS-ZN-NIMs: cellular viability assay  
ZN has been shown to positively influence cell viability and prolif-
eration, possibly due to internalization of its degradation products, 
which has been shown to have antioxidant properties [25]. To deter-
mine the effect of CS-ZN-NIMs on cell viability and overall biocom-
patibility, a series of cellular viability studies were performed (Fig. 
4). HEK293T cells cultured with CS-ZN-NIMs showed significantly 
increased (p ≤ 0.001) viability relative to control cells (Fig. 4A). The 
viability of Caco-2 and RAW 264.7 cells cultured with CS-ZN-NIMs 
was not statistically different compared to vehicle control cells that 
received no treatment, with the exception of CS-ZN-NIMs formed 
with 12 and 15% ZN, which resulted in slightly increased viability 
of Caco-2 cells (p ≤ 0.05 and p ≤ 0.01, respectively) (Fig. 4B and C). 
 
3.5. Simulated gastric fluid release  
Protection of the encapsulated DNA payload from degradation, in 
addition to minimal DNA release in the gastric compartment, is es-
sential to achieving successful gene delivery via the oral route. To 
investigate the release profile of CS/DNA NPs from CS-ZN-NIMs, a 
series of SGF release studies were performed (Fig. 5). The CS-ZN-
NIMs exhibited sustained DNA release for up to 240 min, with par-
ticles formed with 15 and 25% ZN showing a slower rate of release 
when compared to particles formed with 12% ZN for the first 60 min 
of incubation (see Fig. 5 legend for statistics). After 45 min in SGF, a 
time frame similar to the average gastric residence time (from 10 to 
120 min) for fasted human stomachs [49]. CS-ZN-NIMs formed with 
either 15% and 25% ZN still retained 56.9 ± 3.05 and 61.0 ± 10.2% 
of the encapsulated DNA, respectively, while particles formed with 
12% ZN and naked CS NPs retained 35.5 ± 0.8% and 50.2 ± 1.0% of 
encapsulated DNA, respectively (Fig. 5).  
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Figure 1. Characterization of CS/DNA NPs formed via ionic gelation. CS/DNA NPs formed at varying CS:TPP weight ratios were characterized for size 
(circles) and charge (triangles) (A–C), DNA encapsulation efficiency (D–F), and transfection (G–I). The concentration of the CS solution used in parti-
cle formation was held constant at 0.5 mg/mL (A,D and G), 1.0 mg/mL (B, E and H), and 2.0 mg/mL (C, F, and I) for all CS:TPP ratios. All data repre-
sented as mean ± SEM (n = 6). Asterisks (*) denote significance compared to 0.5 mg/mL conditions (*p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001). Plus 
signs (+) denote significance compared to 1.0 mg/mL conditions (++ p ≤ 0.01 and +++ p ≤ 0.001).
Figure 2. Formation of CS-ZN-NIMsusing a single water-in-oil emulsion (W/O). Briefly, CS/DNANPs were formed via ionic gelation as described. The 
formed NPs were added to a 90% aqueous ethanol solution of ZN at varying concentrations (5–25% w/v). The ZN-CS/DNA NPs suspension was then 
added to the continuous phase (corn oil) under constant stirring to form the single W/O emulsion. Solvent evaporation results in ZN microsphere 
solidification, encapsulating the CS/DNA NPs to form CS-ZN-NIMs. The resulting particles were separated from the continuous phase, washed to re-
move oil, and collected. Fig. 3. SEM micrographs of CS-ZN-NIMs formed with varying initial ZN concentrations. (A) 12% zein (530× magnification). 
(B) 15% zein (570× magnification). (C) 25% (680× magnification).
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3.6. SIF treatment of CS-ZN-NIMs: enzyme-mediated release of  
CS/DNA NPs and transfection profiles  
To investigate the ability of CS-ZN-NIMs to release transfection com-
petent CS/DNA NPs in the intestinal compartment, a series of SIF in-
cubations were performed. The CS/DNA NPs released from CS-ZN-
NIMs during incubation were collected and subsequently delivered 
to cells, and the amount of transgene expression was quantified af-
ter a 24-h incubation. For SIF studies, the properties of the inner core 
of CS/DNA NPs loaded into ZN microparticles were held constant 
at 1.0 mg/mL CS, a CS:TPP ratio of 8, and a CS:DNA ratio of 10 (Fig. 
6A). While the overall trend in transgene expression was found to in-
crease with increasing ZN concentration, there were no statistical dif-
ferences in transgene expression with increasing ZN concentrations, 
with the exception of the 5 and 25% ZN conditions (p ≤ 0.05) (Fig. 
6A). However, when incubated in the absence of enzyme, the abil-
ity of all CS-ZN-NIM formulations (formed with any percentage of 
ZN) to mediate transgene expression was dramatically reduced (p ≤ 
0.05 for 10, 12, 15% ZN particles and p ≤ 0.001 for 25% ZN particles), 
demonstrating an intestinal enzyme mediated degradation of the 
ZN microparticles and release of CS/DNA NPs. Next, to ensure that 
the W/O emulsion encapsulation process did not affect the trans-
fection properties of the CS/DNA NPs, a series of transfections fol-
lowing SIF treatment were performed with CS-ZNNIMs loaded with 
CS/DNA NPs formed at CS:DNA ratios of 5, 10 and 25 because low 
CS:DNA ratios have been implicated in improved transfection when 
using low molecular weight CS [50] (Fig. 6B). CS-ZN-NIMs loaded 
with CS/DNANPs at a CS:DNA ratio of 5 and then subjected to SIF 
conditioning resulted in the highest transgene expression, followed 
by particles loaded with CS/DNA NPs formed at CS:DNA ratios of 10 
and 25 (Fig. 6B, see figure legend for a description of statistics). Fi-
nally, CSZN- NIMs were incubated in SIF for varying periods of time 
including 0, 15, 30, and 60 min. Transgene expression increased with 
increasing incubation time in SIF for CS-ZN-NIMs formed from 12, 
15, and 25% ZN (Fig. 6C), further indicating ZN degradation and CS/
DNA NP release is an enzyme-mediated process.  
3.7. In vitro simulation of oral delivery  
To test the ability of the outer ZN microparticle to protect the CS/ 
DNA NPs throughout the whole GI tract, particles formed from 12 
and 15% ZN were subjected to in vitro simulated GI transit (15 min 
in SGF containing pepsin followed by 60 min in SIF containing pan-
creatin). Due to the discrepancy observed in duplicating transfec-
tion (note differences in transfection observed in independent ex-
periments in Fig. 6A and B) with the 25% ZN particles, and the low 
CS/DNA NP loading, we chose to exclude these particles from fur-
ther testing. The resulting NPs were then delivered to HEK293T cells 
(Fig. 7). CS-ZN-NIMs formed with both ZN concentrations were able 
to protect CS/DNA NPs from SGF and release transfection-compe-
tent CS/DNA NPs upon SIF treatment (Fig. 7). CS-ZN-NIMs formed 
with 12 and 15% ZN induced significantly higher transgene expres-
sion when compared to naked CS/DNANPs subjected to the same 
simulated GI treatment (p ≤ 0.05), resulting in 22 and 20-fold in-
creases in transgene expression, respectively (Fig. 7).  
 
3.8. In vivo oral delivery of CS-ZN-NIMs  
Orally delivered DNA has great promise for use in a wide variety of 
preventative and curative therapeutic applications, including DNA 
vaccination against infectious pathogens. To investigate the ability of 
CSZN- NIMs to successfully protect and deliver DNA cargo through 
the GI tract and induce adaptive immune responses in vivo, mice 
were orally dosed with CS-ZN-NIMs encapsulating either 35 or 100 
μg of the pEGFP-LUC plasmid. For these preliminary in vivo stud-
ies we chose 12% ZN particles for their high degree of CS/DNA NP 
loading, as shown in Table 1. Three weeks after a single oral deliv-
ery, fecal samples from each mouse were collected and examined 
for the presence of IgA antibodies against the GFP protein (Fig. 8). 
Mice orally administered CSZN- NIMs developed fecal anti-GFP IgA 
titers comparable to those from control mice immunized intraperi-
toneally with GFP in Addavax (Fig. 8). These IgA titers were also sig-
nificantly greater that those observed in mice given an irrelevant an-
tigen. Moreover, the IgA titers from mice dosed with CS-ZN-NIMs 
Figure 3. SEM micrographs of CS-ZN-NIMs formed with varying initial ZN concentrations. (A) 12% zein (530× magnification). (B) 15% zein (570× 
magnification). (C) 25% (680× magnification).
Table 1. CS-ZN-NIM Size and CS/DNA NP encapsulation and loading in ZN microparticles.
                                   
CS/DNA NP Encapsulation in Zein Microparticles         CS/DNA NP Loading in Zein Microparticles  
                                                                                      (%)                                                              (μg DNA/g Zein)
Zein solution  Average particle 
concentration (%)  size (μm) CS:DNA = 5  CS:DNA = 10  CS:DNA = 25  CS:DNA = 5  CS:DNA = 10  CS:DNA = 25
12  8.76 ± 2.12  72.26 ± 4.0  74.27 ± 3.7  44.46 ± 1.29  185.63 ± 9.48  174.46 ± 22.9  62.60 ± 3.77
15  8.35 ± 0.51  52.15 ± 12.1  79.52 ± 8.9  54.98 ± 14.4  100.07 ± 19.6  157.67 ± 13.8  62.44 ± 10.9
25  10.63 ± 0.24  48.70 ± 19.4  81.17 ± 0.79  44.01 ± 3.22  83.41 ± 9.46  110.25 ± 11.7  29.28 ± 1.75
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were significantly greater than those from mice receiving naked CS/
DNA NPs (p ≤ 0.001 for 35 μg dose and p ≤ 0.01 for 100 μg dose). 
These data demonstrate that CS-ZN-NIMs are capable of protecting 
DNA cargo during intestinal transit such that it can ultimately medi-
ate in vivo gene expression and induce mucosal immune responses. 
 
4. Discussion  
Oral gene delivery has the potential to be an effective delivery strat-
egy for both gene therapy and DNA vaccination applications. How-
ever, gene delivery via the oral route is complicated by the harsh and 
variable conditions of the GI tract. In this study, we describe the de-
velopment of CS-ZN nano-in-microparticles (CS-ZN-NIMs) consist-
ing of inner CS/ DNA NP cores encapsulated in a protective ZN mi-
croparticle, and we demonstrate their potential for mediating oral 
non-viral gene delivery. These materials were selected for their in-
dividual properties that fulfill the requirements of protection in the 
gastric environment, as well as subsequent delivery to target cells 
in the intestine. Moreover, the natural abundance of both materi-
als, coupled with the simple and mild processing conditions used 
in particle formation, allows for simple scale up, which is crucial for 
future clinical applications. 
In the development of the CS-ZN-NIMs oral delivery system, 
full characterization of the CS/DNA core NPs was essential to un-
derstand particle formation variables that affect the transfection ef-
ficiency of the NPs, and therefore the system in its entirety. The use 
of CS as a natural polymer for the development of gene delivery vec-
tors has been widely documented [3,51–53]. The presence of primary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amine groups, with a pKa of approximately 6.5, causes protonation 
at physiological conditions and leads to a net positive charge. This 
property allows CS to electrostatically combine and condense with 
negatively charged plasmid DNA to form nano-sized complexes. In 
this study, we investigated the use of oligosaccharide CS/DNA NPs 
crosslinked with TPP as the non-viral carrier component of our dual 
particle oral delivery system. Previous reports have found that sev-
eral particle formation parameters, including the molecular weight 
and degree of deacetylation of CS, CS concentration, CS:DNA ratio, 
and the CS:TPP ratio are important in determining the size, charge 
and transfection efficiency of CS delivery systems [50,53,54]. Here, 
the size and net positive charge of CS complexes were found to in-
crease as the ratio of CS to TPP increased, which agrees with previ-
ous reports [54,55]. A similar dependence on CS:TPP ratio was ob-
served for the encapsulation efficiency of DNA within CS complexes, 
with decreased encapsulation observed for increasing CS:TPP ratios. 
Finally, the in vitro transfection efficiency of the CS complexes was 
found to be dependent upon both the CS:TPP ratio and the CS con-
centration used in CS formation (Fig. 1). The general trend of de-
creasing transgene expression with increasing CS:TPP ratio is hy-
pothesized to be directly related to the decrease in encapsulation 
efficiency and the increasing size of the complexes observed with in-
creasing CS:TPP ratio, as complex size is a critical factor for efficient 
endocytosis and cellular uptake [56, 57]. The results of these stud-
ies highlight the tunable nature these delivery systems to achieve 
characteristics that are critical to efficient gene delivery, specifically 
size, charge, encapsulation, and transfection efficiency.  
In order to achieve successful gene delivery via the oral route, 
it is critical that the DNA cargo be protected from the highly acidic 
pH of the gastric environment and from degradation by endoge-
nous nucleases, as well as gastric and intestinal enzymes. Oral gene 
delivery systems based on CS have been reported. However, these 
systems achieve only modest success, presumably due to incomplete 
protection in the stomach because of the solubility of CS in acidic 
aqueous conditions [58,59]. To overcome the limitations of CS deliv-
ery systems, we report the use of ZN to further encapsulate the CS/
DNA NPs. ZN has recently received interest as a natural biomaterial 
for a variety of applications including tissue engineering [60–62] and 
drug and gene delivery [26,63] due to its inherent biocompatibility 
and biodegradability. Moreover, ZN, being composed of over 50% 
hydrophobic amino acids, is amphiphilic in nature, which allows it 
to self-assemble into nanoparticles [27] and microparticles [29] as 
well as uniform films that can be used as protective coatings [64]. 
Taking advantages of these properties, ZN has already been used 
in tableting and coating applications in both the food and pharma-
ceutical industries [34,65].  
The use of ZN as a natural material for the encapsulation of ther-
apeutic compounds, including DNA, requires the selection of a suit-
able solvent that is compatible with the compound to be encapsu-
lated. ZN’s amino acid composition renders it insoluble in aqueous 
conditions, and therefore requires a binary solvent for complete 
Figure 4. Biocompatibility of CS-ZN-NIMs incubated with HEK293T (A), Caco-2 (B), and RAW 264.7 (C) cells. Cellular proliferation was measured us-
ing the WST-1 assay and absorbance values were normalized to cells that received no particle treatment. ***, **, and * indicate p ≤ 0.001, 0.01, 0.05, 
respectively for treatments compared to cell control condition. All data represent mean ± SEM (n = 6).
Figure 5. CS/DNA NP release from CS-ZN-NIMs formed with 12% ZN 
(●), 15% ZN(♦), and 25% ZN (■), and DNA release from naked CS/DNA 
NPs (▼) incubated in SGF. The shaded portion of the figure represents 
the mean gastric residence time for solid oral dosage forms in fasted 
human stomachs. All data represent mean ± SEM (n= 3). *, p ≤ 0.05 for 
CS NPs and 12% ZN. +++, p ≤ 0.001 for CS NPs and 15 and 25% ZN. xx, 
p ≤ 0.01 for 12 and 25% ZN. ♦, p ≤ 0.05 for 12 and 15% ZN. +, p ≤ 0.05 
for CS NPs and 15 and 25% ZN. x, p ≤ 0.05 for 12 and 25% ZN.
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solubilization. The most commonly used solvent for ZN is aqueous 
ethanolic solutions between 55 and 90% (v/v) ethanol [66]. To this 
end, various ethanolic ZN solutions were investigated for use in the 
W/O emulsion method developed here (data not shown), which in-
volved a single emulsion of ethanolic ZN into the continuous phase 
of 100% corn oil. It was found that 90% ethanolic solutions of ZN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
resulted in uniform spherical microparticles containing CS/DNA NPs 
at the ZN concentrations investigated in this study. This phenome-
non was likely due to the increased rate of solvent evaporation rel-
ative to lower concentration ethanolic solutions, an important factor 
implicated in the formation of microparticles using emulsion type 
encapsulation processes (data not shown). The addition of the non-
ionic surfactant span-80 resulted in smaller, more uniform particles 
due to increased stability of the interface between the continuous 
(corn oil) and dispersed phases (ethanolic ZNCS/ DNA NP suspen-
sion) of the emulsion system (data not shown). Encapsulation of the 
CS/DNA NPs within ZN microparticles was determined to be depen-
dent upon the concentration of ZN solution used in the W/O emul-
sion. To increase the encapsulation of the positively charged CS/
DNA NPs within the ZN microparticles, the initial pH of the ZN so-
lutions was raised to approximately 9 to impart an overall negative 
charge to the ZN (isoelectric point of ZN is 6.8) [67], leading to an 
increased association of CS/DNA NPs with ZN. Increasing the con-
centration of the ZN solution from 12 to 25% tended to increase the 
encapsulation efficiency of CS/DNA nanoparticles within the ZN mi-
croparticles for CS/DNA NPs formed at a CS:DNA ratio of 10 (Table 
1). This increase could be attributed to the increase in the viscosity 
of the dispersed phase, leading to decreased diffusion of the CS/
DNA NPs from the dispersed phase into the continuous phase dur-
ing the emulsion process [68,69]. Increasing the viscosity of the dis-
persed phase (through increasing ZN concentration) also resulted 
in larger particles (Table 1 and Fig. 2).  
Loading of CS/DNA particles into ZN microparticles reached a 
maximum of ~180 μg DNA/g ZN, which is lower than what has been 
Figure 6. Transgene expression mediated by CS-ZN-NIMs following incubation in simulated intestinal fluid (SIF). (A) The effect of intestinal enzyme-
mediated degradation of CS-ZN-NIMs on transgene expression. Particles formed with varying zein solutions (5, 7, 10, 12, 15, and 25%)were incu-
bated in either SIF containing pancreatin(+SIF) or PBS (−SIF) ***, *, and ns indicate p ≤ 0.001, 0.05, and no significance, respectively for +SIF condi-
tions compared to their respective –SIF condition (n = 6).While the overall trend in transgene expression was found to increase with increasing ZN 
concentration, there were no statistical differences in transgene expression with increasing ZN concentrations, with the exception of the 5 and 25% 
ZN conditions (p ≤ 0.05). (B) Transgene expression of CS-ZN-NIMs formed with varying zein solutions and varying CS/DNA NPs (n = 3). Asterisks 
(*) indicate significance between CS:DNA = 5 and CS:DNA = 10 conditions, ***, and ** p ≤ 0.001 and 0.01, respectively. Plus signs (+) indicate sig-
nificance between CS:DNA = 5 and CS:DNA = 25 conditions, +++, + p ≤ 0.001 and 0.05, respectively. Diamonds (♦) indicate significance between 
CS:DNA = 10 and CS:DNA = 25 conditions ♦♦, ♦ p ≤ 0.01 and 0.05, respectively. (C) Transgene expression mediated by CS-ZN-NIMs after varying 
incubation times in SIF containing pancreatin.
Figure 7. Transgene expression mediated by CS-ZN-NIMs after com-
plete simulated GI tract transit. CS-ZN-NIMs formed with varying ini-
tial zein solutions were subjected to 15 min incubation in SGF contain-
ing pepsin, followed immediately by 60 min incubation in SIF containing 
pancreatin. ** signifies p ≤ 0.01 when compared to naked CS NPs sub-
jected to the same treatment. Fold change increase in transgene ex-
pression over naked CS NPs is shown in parentheses. All data represent 
mean ± SEM (n = 6).
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reported for the loading of hydrophobic molecules into ZN mic-
roparticles [30]. It has been shown previously that hydrophilic mol-
ecules are more difficult to load into ZN nano- and microparticles 
than more hydrophobic molecules, presumably due to decreased 
hydrophobic interactions between the hydrophilic molecules and 
hydrophobic amino acids of the ZN molecule [30,45]. However, the 
maximum encapsulation efficiency of DNA within the ZN micropar-
ticles (~80%) was found to be higher than similar multi-particulate 
systems for DNA delivery [1].  
In previous works, ZN has been shown to have degradation 
products that are beneficial to cellular proliferation, and cells cul-
tured on ZN films have enhanced viability. Further characterization 
of the CS-ZN-NIMs revealed no cytotoxicity in several cell types rel-
evant to oral delivery, including intestinal epithelial cells and mac-
rophages (Fig. 4). These results agree with the extensive field of ev-
idence supporting ZN’s biocompatibility in biomedical applications 
[25,26,37,70,71]. We expect the positive effect of ZN degradation 
products on cell health to be an advantage of the proposed delivery 
system. The rapid degradation of the ZN microparticle in the intes-
tine could lead to an elevated concentration of degradation prod-
ucts in the intestinal environment, which in turn has the potential 
to improve cell health and potentially decrease transfection- asso-
ciated cellular toxicity [25,62].  
Encapsulation of various compounds in ZN, as well as coating 
particles with ZN, have been shown to decrease the release profile 
under simulated gastric conditions [72]. To investigate the ability of 
CS-ZNNIMs to protect the CS/DNA NPs from degradation and re-
duce the release of DNA with the gastric compartment, a series of 
simulated gastric release studies were performed (Fig. 5). CS-ZN-
NIMs formed from 15 and 25% ZN both exhibited a slower release 
of DNA in gastric conditions as compared to un-encapsulated CS/
DNA NPs during a period of time that is representative of the av-
erage gastric residence time in humans. The gastric release profile 
for particles formed with 15 and 25% ZN indicated slower release 
kinetics versus that of particles formed with 12% ZN for the first 60 
min of the release. These data support other studies investigating 
ZN microparticles for oral delivery or evaluating ZN as an enteric 
coating, both of which found that increasing the amount of ZN, ei-
ther to form the coating or during the microparticle formation, led 
to decreased release rates [72–74]. Those studies, in addition to the 
data presented here, suggest that the relative amount of ZN used 
in the preparation of CS-ZN-NIMs influences the protective capa-
bilities of the particles, with increasing amounts of ZN resulting in 
improved protection. It is worth noting that CS/DNA NPs exhibited 
slower release kinetics than CS-ZN-NIMs formed using 12% ZN, an 
unexpected result considering the pKa of the amine groups of CS 
(~6.5). At the low pH of the SGF dissolution media used during the 
SGF release, the amine groups should have been completely pro-
tonated, resulting in electrostatic repulsion between CS polymer 
chains and dissolution of CS NPs at pH 1.2. Although our result was 
surprising and will be the focus of future studies, we would like to 
highlight that the ZN coating not only serves to slow DNA release, 
but also to protect the structure and properties of the CS/DNA NPs 
to allow efficient cellular transfection. This protective effect was ev-
ident in our in vitro simulated GI transit studies (Fig. 7) as well as in 
our in vivo oral delivery study (Fig. 8). Further, data from our release 
studies indicate that CS-ZN-NIMs formed with 12, 15 and 25% ZN 
retain 49, 71 and 77%, respectively, of the encapsulated DNA after 
a 30-min incubation in SGF (Fig. 5). Although gastric residence and 
emptying time can vary widely between individuals, foremost solid 
uniform oral dosage forms the gastric residence time in fasted hu-
man stomachs is on the order of 10–120 min, with an average res-
idence time of ~45 min [49]. Therefore, given the appropriate dos-
ing schedule and regimen, CS-ZN-NIMs have the potential to reach 
the small intestine with nearly 50–70% of the CS/DNA NP cargo re-
maining intact with the potential to achieve successful transfection. 
To better understand the DNA encapsulation characteristics, as 
well as assess the ability of CS-ZN-NIMs to release CS/DNA NPs in 
a site-specific manner for DNA delivery in the small intestine, a se-
ries of in vitro SIF incubations and transfection experiments were 
performed. CS-ZNNIMs incubated in SIF containing pancreatin for 
60 min were found to mediate transfection in HEK293T cells, with 
an increase in transgene expression observed for particles formed 
with increasing concentration of the ZN solutions used in the W/O 
emulsion. Moreover, the ability of the CS-ZN-NIMs to mediate trans-
fection was found to be dependent on the intestinal enzyme-medi-
ated degradation of the ZN microparticles, as transgene expression 
was negligible when particles were incubated in PBS (i.e., no deg-
radation of the outer ZN microparticle) (Fig. 6). These data support 
previous work from us [26] and others and indicate that non-enzy-
matic hydrolytic degradation of ZN microparticles occurs very slowly, 
further supporting the use of ZN in oral applications [29]. The lack 
of transgene expression from particles incubated in PBS also indi-
cates complete encapsulation of the CS/DNANPs within the ZN mi-
croparticles as opposed to surface adsorption, further confirming 
the high encapsulation efficiencies observed. Furthermore, CS-ZN-
NIMs incubated in SIF for varying amounts of time showed increas-
ing transgene expression as incubation time increased (Fig. 6C). The 
time-dependence of transgene expression levels observed after SIF 
incubation of CS-ZNNIMs further indicates that the degradation of 
ZN is an enzyme-mediated process occurring over a period of ap-
proximately 1 h, leading to sustained release of CS/DNA NPs.  
In addition to simulated gastric release and intestinal delivery, 
in vitro simulations of complete GI transit were performed to dem-
onstrate the feasibility of the CS-ZN-NIMs as an oral gene deliv-
ery system. Both CS-ZN-NIMs and un-encapsulated, bare CS/DNA 
NPs were subjected to sequential simulated gastric and simulated 
intestinal fluid and then assessed for their ability to mediate trans-
gene expression in HEK293T cells. Only cells treated with GI-condi-
tioned CS-ZN-NIMs resulted in luciferase expression, whereas na-
ked CS/DNA NPs subjected to the same treatment did not produce 
any transgene expression. These results indicate that encapsulation 
of the CS/DNA NPs within the ZN microparticles not only delays the 
release of CS/DNA NPs in the gastric environment and allows for 
Figure 8. Anti-GFP IgA titers following a single oral delivery of CS-ZN-
NIMs. CS-ZN-NIM amounts equivalent to 35 and 100 μg of pEGFP-LUC 
were delivered to 6-week old male BALB/c mice via oral gavage. Three 
weeks after gavage, fecal samples were collected, diluted 1:20 w/v in PBS 
and anti-GFP IgA antibody titers were evaluated using an ELISA assay. 
Fecal samples from mice immunized with non-GFP antigen was used as 
a negative control. Endpoint titers were determined using the optical 
densities measured for the negative control as a cutoff for endpoint di-
lutions. (*** p ≤ 0.001, ** p ≤ 0.01).
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DNA release in the small intestine, but it also protects the structure 
of the CS/DNA NPs essential for achieving successful gene delivery. 
The protection of gene delivery vectors and their release in the 
intestinal compartment has important implications for oral delivery 
applications including gene therapy, which requires the delivery of 
the therapeutic gene to the local site of inflammation, and DNA vac-
cines, which have the potential to transfect immune cells of the gut-
associated lymphoid tissues to produce mucosal and systemic im-
munity. To this end, CS-ZN-NIMs were evaluated for their ability to 
protect CS/DNA NPs and mediate effective transfection in vivo in 
mice, and more specifically for their ability to elicit an immune re-
sponse to the encoded model antigen, GFP (Fig. 8). For the purposes 
of this study, we chose to investigate the ability of CS-ZN-NIMs to 
induce the production of anti- GFP IgA antibodies as a measure of 
both transgene expression and immune induction in the small in-
testine. This indirect measure of transgene expression allowed us to 
overcome limitations in directly quantifying fluorescent transgene 
expression due to the auto-fluorescent signal of degraded Zain [26]. 
Future studies will aim to directly evaluate transgene expression 
through fluorescence microscopy and measuring in vivo lumines-
cence using a luciferase reporter gene, to confirm the preliminary 
evidence of GFP expression in the intestinal mucosa presented here. 
The presence of anti-GFP IgA antibodies in feces following oral 
delivery of CS-ZN-NIMs indicates adequate protection and release 
of CS/DNA NPs and the subsequent successful transfection and pro-
duction of the GFP protein by cells in vivo. Anti-GFP IgA titers in 
some mice given CS-ZN-NIMs were as high as titers in mice given 
GFP protein in Addavax as a positive control, again indicating that 
sufficient transgene expression and subsequent protein production 
occurred. IgA antibodies are predominately associated with muco-
sal immune responses in the intestinal tract [75]. To induce such re-
sponses, antigen-activated B cells migrate to the periphery of B-cell 
follicles where they undergo maturation and expansion into primar-
ily short-lived, IgM secreting cells that contribute to the first wave of 
antigen-specific antibody production by the adaptive immune re-
sponse [76]. Further interaction of antigen-specific B cells with ac-
tivated CD4+ T cells through CD40-CD40L receptor-ligand binding 
induces class-switch recombination in B cells, allowing for the pro-
duction of other antibody isotypes, including IgA. Our data provide 
evidence of GFP production following oral delivery of CS-ZN-NIMs, 
and suggest that subsequent sampling by APCs, either DCs or B 
cells themselves, resulted in the induction of an adaptive humoral 
immune response. Even with these results, further investigation into 
the ability of this delivery system to induce high affinity, neutraliz-
ing IgG antibodies and antigen-specific cytotoxic T cell responses 
will be required should this delivery system be used for DNA vac-
cination applications. Nonetheless, these data combined highlight 
the potential of CS-ZN-NIMs as an oral delivery system for improv-
ing gene delivery and DNA vaccination.  
 
5. Conclusions  
In this study, we have described the development and characteriza-
tion of a multi-component particulate delivery system for oral gene 
delivery. We have successfully fabricated CS/DNA NPs of tunable size, 
charge, and transfection efficiency and successfully encapsulated 
them into ZN microparticles using a simple W/O emulsion technique. 
The resulting CS-ZN-NIMs exhibited tunable CS/DNA NP loading, 
high encapsulation efficiencies, protection within gastric conditions, 
and intestinal enzyme-mediated release of transfection-competent 
CS/DNA NPs that were capable of mediating transfection in vitro. We 
also demonstrated the ability of CS-ZN-NIMs to successfully medi-
ate transfection in vivo, with evidence of the induction of a primary 
immune response against the encoded model antigen. Future stud-
ies will further investigate the potential of CS-ZN-NIMs for oral DNA 
vaccination in vivo, improve CS/DNA NP loading, and fully character-
ize the induction of the immune response generated by CS-ZN-NIMs. 
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